Total revenues (reported and adjusted) increased by 11.4% (AER) year over year to £259.9 million. Gross margin improved by 60 basis points in FY19, compared to the previous year, to 70.5%. Reported profit before tax declined 18.4% year over year to £56.4 million. Diluted earnings per share (reported) was 21.8 pence compared to 30.2 pence in FY 2018. The company entered into 57 new agreements with biopharmaceutical and diagnostic companies during the year.

On 9th September 2019, at the time of writing, GMT 12:11 PM, ABC shares were trading at GBX 1139.00, down by 101 points or 8.14% against the previous day closing price.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK